NEW YORK (GenomeWeb News) – PamGene International announced today that it has entered into a co-marketing pact with Invitrogen covering nuclear hormone receptor products.
Under the alliance, the firms will co-market Invitrogen’s nuclear hormone receptor proteins and Lanthascreen assay technology with PamGene’s microarray-based nuclear hormone receptor screening tools including its PamChip applications and PamStation instruments.